Authors

Latest:

Nivolumab Alone or With Ipilimumab Controls Disease, Extends Survival, in Mesothelioma

Nivolumab as monotherapy or in combination with ipilimumab may present a new second- or third-line treatment option for patients with malignant pleural mesothelioma, based on preliminary findings from a phase II trial where nivolumab alone or in the combination improved disease control and prolonged survival in patients with this rare but aggressive cancer.

Lauren Mays Weddle, PhD

Latest:

Hepatocellular Carcinoma Surveillance in Focus

Controversy over optimal surveillance methods for hepatocellular carcinoma continues to drive ongoing investigation into improved biomarkers and imaging techniques.

Lauren Nye, MD

Latest:

Dr Nye on Paradigm Shifts in the Management of HR+ Breast Cancer

Lauren E. Nye, MD, discusses how the expansion of targeted therapies in metastatic hormone receptor–positive breast cancer has shifted management approaches.

Lauren Pinter-Brown, MD

Latest:

Dr. Pinter-Brown Discusses Treatment Decisions for CTCL

Lauren Pinter-Brown, MD, Clinical Professor, Department of Medicine, Hematology-Oncology, University of California, Los Angeles, discusses the treatment of cutaneous T-cell lymphoma.

Lauren Zoeller

Latest:

Experts Emphasize Therapy Options, Expanded Mutation Testing in mCRC

Confusion persists about the best choice of frontline therapy for patients with metastatic colorectal cancer (mCRC) after a landmark clinical trial that was conceived a decade ago to answer that question concluded without a superiority finding

Laurence Albiges, MD

Latest:

Dr. Albiges on Next Steps for Immunotherapy in RCC

Laurence Albiges, MD, &lrm;medical oncologist, head, Genitourinary Oncology Unit, Gustave Roussy, discusses the next steps for immunotherapy for patients with renal cell carcinoma (RCC).

Laurence Albiges, MD, PhD

Laurence Albiges, MD, PhD, is head of the Department of Oncology at Institut Gustave Roussy

Latest:

Dr Albiges on the Efficacy of Lenvatinib Plus Belzutifan in ccRCC

Laurence Albiges, MD, PhD, discusses the clinical implications of preliminary efficacy data observed with belzutifan plus lenvatinib in advanced ccRCC.

Laurence J. Heifetz, MD

Latest:

Dr. Heifetz Discusses Rural Oncology Care

Laurence J. Heifetz, MD, medical director, Gene Upshaw Memorial Tahoe Forest Cancer Center, discusses rural oncology care.

Laurie E. Gaspar, MD

Latest:

Dr. Gaspar on a Physician Survey on Prophylactic Cranial Irradiation in SCLC

Laurie E. Gaspar, MD, professor, Radiation Oncology, University of Colorado Denver, discusses a survey she conducted for physicians on the use of prophylactic cranial irradiation for patients with limited small cell lung cancer.

Laurie Gaspar, MD

Latest:

Dr. Gaspar on Treating Brain Metastases in Lung Cancer

Laurie Gaspar, MD, professor and chair of the Department of Radiation Oncology, Grohne Chair in Clinical Oncology, University of Colorado School of Medicine, discusses the treatment of brain metastases in patients with lung cancer.

Laurie H. Sehn, MD, MPH

Latest:

Future Directions and Unmet Needs in Relapsed/Refractory MCL

A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.

Laurie H. Sehn, MD, MPH, BC Cancer

Lavanya Palavalli Parsons, MD

Latest:

Dr. Parsons Discusses the Role of PARP 7 in Overall Survival of Patients With Ovarian Cancer

Lavanya Palavalli Parsons, MD, clinical fellow, The University of Texas Southwestern Medical Center, discusses the role of PARP 7 in overall survival of patients with ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.

Lawrence B. Afrin, MD

Latest:

What I Have Learned Since Fellowship: Tips for Professional Success and Happiness

Tips for success from Lawrence B. Afrin, MD an associate professor of medicine in the Division of Hematology/Oncology at Medical University of South Carolina in Charleston.

Lawrence B Berk, MD, PhD

Latest:

A Comprehensive Review of Hemibody Irradiation for Patients with Bone Metastases

A comprehensive review was initiated on hemibody irradiation for patients with solid tumors with an emphasis on bone metastases to determine the efficacy and the toxicity of this treatment.

Lawrence D. Kaplan, MD

Latest:

Dr. Kaplan on Research With Bispecific Monoclonal Antibodies in Follicular Lymphoma

Lawrence D. Kaplan, MD, discusses research with bispecific monoclonal antibodies in follicular lymphoma.

Lawrence E. Feldman, MD

Latest:

Dr. Feldman on Lenvatinib and Pembrolizumab Plus Chemotherapy in NSCLC

Lawrence E. Feldman, MD, discusses the phase 3 LEAP-006 trial evaluating lenvatinib and pembrolizumab plus chemotherapy in non–small cell lung cancer.

Lawrence Fong, MD

Latest:

Dr. Lawrence Fong on Managing the Side Effects of Immunotherapies

Lawrence Fong, MD, Professor, Department of Medicine (Hematology/Oncology), University of California San Francisco, discusses the importance of educating oncologists on the side effects of immunotherapies.

Lawrence H. Einhorn, MD

Latest:

Dr. Einhorn on Improving the Cure Rate and the Burden of Cure in Prostate Cancer

Lawrence H. Einhorn, MD, distinguished professor of medicine, division of hematology/oncology, Indiana University School of Medicine, Giant of Cancer Care: Genitourinary Cancer, discusses new methods being explored to help improve the cure rate in prostate cancer.

Lawrence I. Karsh, MD

Latest:

Hereditary Prostate Cancer—What Urologists Should Know

Historically, urologists have been the primary caretakers for men with localized prostate cancer, which is the most prevalent solid tumor in men over 50 years of age and the second-leading cause of cancer-specific mortality in the United States today.